KRAS G12C clinical trials at UCSF

1 research study open to eligible people

KRAS G12C is a gene mutation found in some cancers. UCSF is testing a new drug called FMC-376 for people with solid tumors that have this mutation. These trials aim to find out how well FMC-376 works and how safe it is for patients.

Showing trials for

  • FMC-376 in Participants with KRAS G12C Mutated Solid Tumors

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

    San Francisco, California and other locations

Our lead scientists for KRAS G12C research studies include .

Last updated: